MCET (MultiCell Technologies) Forward Dividend Yield %: 0.00% (As of Jul. 10, 2026)


What is MultiCell Technologies Forward Dividend Yield %?

MultiCell Technologies MCET -90.00% Forward Dividend Yield % is 0.00% as of Jul. 10, 2026.

As of today (2026-07-10), the Forward Annual Dividend Yield of MultiCell Technologies is 0.00%.

As of today (2026-07-10), the Trailing Annual Dividend Yield of MultiCell Technologies is 0.00%.

MCET's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Forward Dividend Yield % only.

MultiCell Technologies's Dividends per Share for the three months ended in Aug. 2015 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

MultiCell Technologies  (OTCPK:MCET) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

MultiCell Technologies Forward Dividend Yield % Related Terms

MCET vs ERGO, OPLI, GLAG: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, MultiCell Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MultiCell Technologies Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Forward Dividend Yield % falls into.


MultiCell Technologies Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
MultiCell Technologies (MCET) has a Forward Dividend Yield % of 0.00% as of Jul. 10, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Forward Dividend Yield % too high?
MultiCell Technologies' current Forward Dividend Yield % is 0.00%.
How does MultiCell Technologies' Forward Dividend Yield % compare to ERGO and OPLI?
MultiCell Technologies' Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.31, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on MultiCell Technologies and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MultiCell Technologies's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Forward Dividend Yield % is 0.00% as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.